BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang L, Li H. MiR-770-5p facilitates podocyte apoptosis and inflammation in diabetic nephropathy by targeting TIMP3. Biosci Rep 2020;40:BSR20193653. [PMID: 32309847 DOI: 10.1042/BSR20193653] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Xie J, Chen Z, Yao G, Yuan Y, Yu W, Zhu Q. NUP160 knockdown inhibits the progression of diabetic nephropathy in vitro and in vivo. Regenerative Therapy 2022;21:87-95. [DOI: 10.1016/j.reth.2022.05.011] [Reference Citation Analysis]
2 Ramanjaneya M, Priyanka R, Bensila M, Jerobin J, Pawar K, Sathyapalan T, Abou-samra AB, Halabi NM, Moin ASM, Atkin SL, Butler AE. MiRNA and associated inflammatory changes from baseline to hypoglycemia in type 2 diabetes. Front Endocrinol 2022;13:917041. [DOI: 10.3389/fendo.2022.917041] [Reference Citation Analysis]
3 Song L, Feng S, Yu H, Shi S. Dexmedetomidine Protects Against Kidney Fibrosis in Diabetic Mice by Targeting miR-101-3p-Mediated EndMT. Dose-Response 2022;20:155932582210834. [DOI: 10.1177/15593258221083486] [Reference Citation Analysis]
4 Yun J, Ren J, Liu Y, Dai L, Song L, Ma X, Luo S, Song Y. MicroRNA (miR)-590-3p alleviates high-glucose induced renal tubular epithelial cell damage by targeting C-X3-C motif chemokine ligand 1 (CX3CL1) in diabetic nephropathy. Bioengineered 2022;13:634-44. [PMID: 34898373 DOI: 10.1080/21655979.2021.2012548] [Reference Citation Analysis]
5 Casagrande V, Federici M, Menghini R. TIMP3 involvement and potentiality in the diagnosis, prognosis and treatment of diabetic nephropathy. Acta Diabetol 2021;58:1587-94. [PMID: 34181080 DOI: 10.1007/s00592-021-01766-y] [Reference Citation Analysis]
6 Shao BY, Zhang SF, Li HD, Meng XM, Chen HY. Epigenetics and Inflammation in Diabetic Nephropathy. Front Physiol 2021;12:649587. [PMID: 34025445 DOI: 10.3389/fphys.2021.649587] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
7 Wang M, Wei J, Ji T, Zang K. miRNA-770-5p expression is upregulated in patients with type 2 diabetes and miRNA-770-5p knockdown protects pancreatic β-cell function via targeting BAG5 expression. Exp Ther Med 2021;22:664. [PMID: 33986829 DOI: 10.3892/etm.2021.10096] [Reference Citation Analysis]
8 Jiang Z, Tan J, Yuan Y, Shen J, Chen Y. LncRNA SNHG1 suppresses LPS-induced acute lung injury by regulating miR-421/TIMP3 axis.. [DOI: 10.1101/2021.02.04.429871] [Reference Citation Analysis]
9 Gu YY, Lu FH, Huang XR, Zhang L, Mao W, Yu XQ, Liu XS, Lan HY. Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Front Pharmacol 2020;11:583528. [PMID: 33574750 DOI: 10.3389/fphar.2020.583528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
10 Wang M, Zheng H, Zhou X, Zhang J, Shao G. miR-122 promotes diabetic retinopathy through targeting TIMP3. Anim Cells Syst (Seoul) 2020;24:275-81. [PMID: 33209201 DOI: 10.1080/19768354.2020.1816580] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Peters LJF, Floege J, Biessen EAL, Jankowski J, van der Vorst EPC. MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application. Int J Mol Sci 2020;21:E6547. [PMID: 32906849 DOI: 10.3390/ijms21186547] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
12 Fan D, Kassiri Z. Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Its Therapeutic Implications in Cardiovascular Pathology. Front Physiol 2020;11:661. [PMID: 32612540 DOI: 10.3389/fphys.2020.00661] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]